Just watched the webinar, thanks to everyone who contributed their views in respect to what Jon covered in the webinar. I don't have much else to contribute except to say that someone asked a pertinent question regarding whether Neuren would provide R&D expenditure, to which he replied because Neuren still hasn't decided which way to go in regards to further developing 2591 they couldn't provide guidance yet if at all.
I found this comment particularly striking that even now in preparation for a Phase 3 trial for PMS they haven't firmed up on which way to go. Perhaps Jon has a better idea already but is being coy, though it is peculiar to see a company at this point and still have no clear direction.
Kudos to Jon for fronting the webinar, he looked tired and even slightly agitated. Possibly jetlagged or constantly harangued by retail investors on the phone about the Culper report lol, the guy is human after all...
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)